KRT13
Reaktivität: Human
WB, ELISA
Wirt: Maus
Monoclonal
4F5
unconjugated
Applikationshinweise
Optimal dilution of the Cytokeratin 13 antibody should be determined by the researcher.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
1 mg/mL in 1X PBS, BSA free, sodium azide free
Konservierungsmittel
Azide free
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store the Cytokeratin 13 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Target
Cytokeratin 13 (KRT13)
(Keratin 13 (KRT13))
Andere Bezeichnung
Cytokeratin 13
Hintergrund
Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs)that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratins 10 and 13 are present in the cytoskeletal region of a subset of squamous cell carcinomas. Cytokeratin 13 belongs to the intermediate filament family and is a heterotetramer of two type I acidic and two type II basic keratins. It is generally associated with Cytokeratin 4. Defects in the KRT13 gene are a cause of white sponge nevus of cannon (WSN), a rare autosomal dominant disorder which predominantly affects noncornified stratified squamous epithelia and is characterized by the presence of soft, white and spongy plaques in the oral mucosa.